Fang Dong, Ren Da, Zhao Chenglin, Li Xuesong, Yu Wei, Wang Rui, Wang Huihui, Xi Chenguang, He Qun, Wang Xiaoying, Xin Zhongcheng, Zhou Liqun
Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.
Department of Radiology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.
Biomed Res Int. 2015;2015:596797. doi: 10.1155/2015/596797. Epub 2015 Oct 18.
To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA) 4-10 ng/mL and develop a risk-stratification score model.
The data of 345 patients who underwent transrectal ultrasound-guided prostate biopsy between 2011 and 2013 was retrospectively analyzed. Digital rectal examination (DRE), prostate volume (PV), magnetic resonance imaging (MRI), and smoking status were also collected. Positive biopsy outcomes were defined as prostate cancer (PCa) and high grade PCa (HGPCa, Gleason Score ≥ 7).
The median PSA was 7.15 (IQR 5.91-8.45) ng/mL. Overall 138 patients (40.0%) were shown to have PCa, including 100 patients (29.0%) with HGPCa. Smaller PV, elder age, MRI results, and positive DRE were proved to be predictive factors for positive biopsy outcomes in both univariate and multivariate analysis. We developed a "PAMD" score which combined the four factors to categorize patients into three risk groups, and the model performed good predictive sensitivity and specificity.
The prevalence of prostate cancer in Chinese patients with PSA 4-10 ng/mL was 40%, including 29% patients with high grade disease. DRE, age, MRI, and PV were predictive factors for positive biopsy outcomes, and the PAMD score model could be utilized for risk-stratification and decision-making.
阐明中国前列腺特异性抗原(PSA)为4 - 10 ng/mL的患者活检阳性结果的特征及危险因素,并建立风险分层评分模型。
回顾性分析2011年至2013年间345例行经直肠超声引导下前列腺活检患者的数据。还收集了直肠指检(DRE)、前列腺体积(PV)、磁共振成像(MRI)及吸烟状况。活检阳性结果定义为前列腺癌(PCa)和高级别前列腺癌(HGPCa, Gleason评分≥7)。
PSA中位数为7.15(四分位间距5.91 - 8.45)ng/mL。总体上138例患者(40.0%)被证实患有PCa,其中100例患者(29.0%)患有HGPCa。单因素和多因素分析均证实较小的PV、老年、MRI结果及阳性DRE是活检阳性结果的预测因素。我们开发了一个“PAMD”评分,将这四个因素结合起来将患者分为三个风险组,该模型具有良好的预测敏感性和特异性。
中国PSA为4 - 10 ng/mL的患者中前列腺癌患病率为40%,其中29%为高级别疾病。DRE、年龄、MRI和PV是活检阳性结果的预测因素,PAMD评分模型可用于风险分层和决策制定。